Prellis Biologics Company
Prellis employs holographic tissue printing technology with fully human antibody discovery, in vitro human disease and ADME/Tox models.
Technology:
Organoids, Small Molecules
Industry:
BioEngineering, Providers
Headquarters:
San Francisco, California, United States
Founded Date:
2016-01-01
Employees Number:
11-50
Funding Status:
Late Stage Venture
Investors Number:
12
Total Funding:
64872758
Estimated Revenue:
$1M to $10M
Last Funding Date:
2022-08-10
Last Funding Type:
Series C
Register and Claim Ownership